6/2/2014 9:40:58 AM
NATICK, Mass., May 31, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an ongoing Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with hematologic malignancies at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. The data indicate that first-in-class oral Selinexor showed continued evidence of anti-cancer activity as a single agent in patients with heavily pretreated Non-Hodgkin's Lymphoma (NHL) and Acute Myeloid Leukemia (AML) who had progressive disease on study entry.
Help employers find you! Check out all the jobs and post your resume.
comments powered by